Global Sepsis Diagnostics

Sepsis Diagnostics Comprehensive Study by Type (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Microfluidics, Biomarkers), Products (Blood Culture Media, Assays & Reagents, Instruments, Software), Technology (Blood Culture, Immunoassays, Molecular Diagnostics), Teste types (Blood tests, Confirmatory Tests, Imaging tests, Laboratory Tests, Point-of-Care Tests), Method (Automated Diagnostics, Conventional Diagnostics), End User (Hospitals, Pathology & Reference Laboratories, Research Laboratories & Academic Institute) Players and Region - Global Market Outlook to 2030

Sepsis Diagnostics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Sepsis Diagnostics
Sepsis is a potentially life-threatening condition that occurs when the body's response to an infection damages its own tissues. When the infection-fighting processes turn on the body, they cause organs to function poorly and abnormally. The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the rising prevalence of sepsis across the globe. Factors such as the increasing geriatric population, a growing number of surgical procedures, a high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are expected to drive market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.8%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Sepsis Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

bioMérieux (France), Becton Dickinson Company (United States), Danaher (United States), Abbott Laboratories (United States), Roche Diagnostics (Switzerland), T2 Biosystems (United States), Luminex (United States), Thermo Fisher Scientific (United States), Bruker (United States), EKF Diagnostics (United Kingdom) and Immunexpress (Australia) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Response Biomedical (Canada), Axis-Shield Diagnostics (United Kingdom) and CytoSorbents (United States)..

Segmentation Overview
AMA Research has segmented the market of Global Sepsis Diagnostics market by Type (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Microfluidics and Biomarkers) and Region.



On the basis of geography, the market of Sepsis Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Products, the sub-segment i.e. Blood Culture Media will boost the Sepsis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Blood Culture will boost the Sepsis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Teste types, the sub-segment i.e. Blood tests will boost the Sepsis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Method, the sub-segment i.e. Automated Diagnostics will boost the Sepsis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Sepsis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing use of hospice for end-of-life care

Market Growth Drivers:
The demand for sepsis diagnostics is increasing due to the burden of sepsis-associated mortality has increased owing to the marked rise in the number of sepsis cases and Ongoing efforts by clinicians, administrators, policymakers, and patient advocates to increase sepsis awareness, screening, and recognition are leading to more patients being labelled with sepsis

Challenges:
The high cost of automated diagnostic devices

Restraints:
Lack of a gold standard test and subjectivity in diagnosing sepsis

Opportunities:
Increasing awareness of sepsis among providers is a major focus of the Surviving Sepsis Campaign and of many quality improvement initiatives that have proliferated in hospitals around the world.

Market Leaders and their expansionary development strategies
In April 2020 CytoVale United States-based, a commercial physical and biological research and development firm. The firm will expand its partnership with the Biomedical Advanced Research and Development Authority(BARDA), to examine the use of Cytovale’s Rapid Sepsis Diagnostic System for diagnosing sepsis in patients with potential respiratory infections, including COVID-19, according to a press release.
In October 2020 IMMUNEXPRESS a molecular diagnostic company and a pioneer in the analysis of the immune system to rapidly detect sepsis. The company launched the test for sepsis in Europe on Biocartis’ Idylla platform. SeptiCyte® RAPID is a one-hour molecular diagnostic test running on the Biocartis Idylla platform that can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Sepsis Diagnostics Providers, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
  • Microfluidics
  • Biomarkers
By Products
  • Blood Culture Media
  • Assays & Reagents
  • Instruments
  • Software

By Technology
  • Blood Culture
  • Immunoassays
  • Molecular Diagnostics

By Teste types
  • Blood tests
  • Confirmatory Tests
  • Imaging tests
  • Laboratory Tests
  • Point-of-Care Tests

By Method
  • Automated Diagnostics
  • Conventional Diagnostics

By End User
  • Hospitals
  • Pathology & Reference Laboratories
  • Research Laboratories & Academic Institute

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The demand for sepsis diagnostics is increasing due to the burden of sepsis-associated mortality has increased owing to the marked rise in the number of sepsis cases
      • 3.2.2. Ongoing efforts by clinicians, administrators, policymakers, and patient advocates to increase sepsis awareness, screening, and recognition are leading to more patients being labelled with sepsis
    • 3.3. Market Challenges
      • 3.3.1. The high cost of automated diagnostic devices
    • 3.4. Market Trends
      • 3.4.1. Increasing use of hospice for end-of-life care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sepsis Diagnostics, by Type, Products, Technology, Teste types, Method, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Sepsis Diagnostics (Value)
      • 5.2.1. Global Sepsis Diagnostics by: Type (Value)
        • 5.2.1.1. Microbiology
        • 5.2.1.2. Molecular Diagnostics
        • 5.2.1.3. Immunoassays
        • 5.2.1.4. Flow Cytometry
        • 5.2.1.5. Microfluidics
        • 5.2.1.6. Biomarkers
      • 5.2.2. Global Sepsis Diagnostics by: Products (Value)
        • 5.2.2.1. Blood Culture Media
        • 5.2.2.2. Assays & Reagents
        • 5.2.2.3. Instruments
        • 5.2.2.4. Software
      • 5.2.3. Global Sepsis Diagnostics by: Technology (Value)
        • 5.2.3.1. Blood Culture
        • 5.2.3.2. Immunoassays
        • 5.2.3.3. Molecular Diagnostics
      • 5.2.4. Global Sepsis Diagnostics by: Teste types (Value)
        • 5.2.4.1. Blood tests
        • 5.2.4.2. Confirmatory Tests
        • 5.2.4.3. Imaging tests
        • 5.2.4.4. Laboratory Tests
        • 5.2.4.5. Point-of-Care Tests
      • 5.2.5. Global Sepsis Diagnostics by: Method (Value)
        • 5.2.5.1. Automated Diagnostics
        • 5.2.5.2. Conventional Diagnostics
      • 5.2.6. Global Sepsis Diagnostics by: End User (Value)
        • 5.2.6.1. Hospitals
        • 5.2.6.2. Pathology & Reference Laboratories
        • 5.2.6.3. Research Laboratories & Academic Institute
      • 5.2.7. Global Sepsis Diagnostics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Sepsis Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioMérieux (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton Dickinson Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. T2 Biosystems (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Luminex (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bruker (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. EKF Diagnostics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Immunexpress (Australia)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Sepsis Diagnostics Sale, by Type, Products, Technology, Teste types, Method, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Sepsis Diagnostics (Value)
      • 7.2.1. Global Sepsis Diagnostics by: Type (Value)
        • 7.2.1.1. Microbiology
        • 7.2.1.2. Molecular Diagnostics
        • 7.2.1.3. Immunoassays
        • 7.2.1.4. Flow Cytometry
        • 7.2.1.5. Microfluidics
        • 7.2.1.6. Biomarkers
      • 7.2.2. Global Sepsis Diagnostics by: Products (Value)
        • 7.2.2.1. Blood Culture Media
        • 7.2.2.2. Assays & Reagents
        • 7.2.2.3. Instruments
        • 7.2.2.4. Software
      • 7.2.3. Global Sepsis Diagnostics by: Technology (Value)
        • 7.2.3.1. Blood Culture
        • 7.2.3.2. Immunoassays
        • 7.2.3.3. Molecular Diagnostics
      • 7.2.4. Global Sepsis Diagnostics by: Teste types (Value)
        • 7.2.4.1. Blood tests
        • 7.2.4.2. Confirmatory Tests
        • 7.2.4.3. Imaging tests
        • 7.2.4.4. Laboratory Tests
        • 7.2.4.5. Point-of-Care Tests
      • 7.2.5. Global Sepsis Diagnostics by: Method (Value)
        • 7.2.5.1. Automated Diagnostics
        • 7.2.5.2. Conventional Diagnostics
      • 7.2.6. Global Sepsis Diagnostics by: End User (Value)
        • 7.2.6.1. Hospitals
        • 7.2.6.2. Pathology & Reference Laboratories
        • 7.2.6.3. Research Laboratories & Academic Institute
      • 7.2.7. Global Sepsis Diagnostics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sepsis Diagnostics: by Type(USD Million)
  • Table 2. Sepsis Diagnostics Microbiology , by Region USD Million (2018-2023)
  • Table 3. Sepsis Diagnostics Molecular Diagnostics , by Region USD Million (2018-2023)
  • Table 4. Sepsis Diagnostics Immunoassays , by Region USD Million (2018-2023)
  • Table 5. Sepsis Diagnostics Flow Cytometry , by Region USD Million (2018-2023)
  • Table 6. Sepsis Diagnostics Microfluidics , by Region USD Million (2018-2023)
  • Table 7. Sepsis Diagnostics Biomarkers , by Region USD Million (2018-2023)
  • Table 8. Sepsis Diagnostics: by Products(USD Million)
  • Table 9. Sepsis Diagnostics Blood Culture Media , by Region USD Million (2018-2023)
  • Table 10. Sepsis Diagnostics Assays & Reagents , by Region USD Million (2018-2023)
  • Table 11. Sepsis Diagnostics Instruments , by Region USD Million (2018-2023)
  • Table 12. Sepsis Diagnostics Software , by Region USD Million (2018-2023)
  • Table 13. Sepsis Diagnostics: by Technology(USD Million)
  • Table 14. Sepsis Diagnostics Blood Culture , by Region USD Million (2018-2023)
  • Table 15. Sepsis Diagnostics Immunoassays , by Region USD Million (2018-2023)
  • Table 16. Sepsis Diagnostics Molecular Diagnostics , by Region USD Million (2018-2023)
  • Table 17. Sepsis Diagnostics: by Teste types(USD Million)
  • Table 18. Sepsis Diagnostics Blood tests , by Region USD Million (2018-2023)
  • Table 19. Sepsis Diagnostics Confirmatory Tests , by Region USD Million (2018-2023)
  • Table 20. Sepsis Diagnostics Imaging tests , by Region USD Million (2018-2023)
  • Table 21. Sepsis Diagnostics Laboratory Tests , by Region USD Million (2018-2023)
  • Table 22. Sepsis Diagnostics Point-of-Care Tests , by Region USD Million (2018-2023)
  • Table 23. Sepsis Diagnostics: by Method(USD Million)
  • Table 24. Sepsis Diagnostics Automated Diagnostics , by Region USD Million (2018-2023)
  • Table 25. Sepsis Diagnostics Conventional Diagnostics , by Region USD Million (2018-2023)
  • Table 26. Sepsis Diagnostics: by End User(USD Million)
  • Table 27. Sepsis Diagnostics Hospitals , by Region USD Million (2018-2023)
  • Table 28. Sepsis Diagnostics Pathology & Reference Laboratories , by Region USD Million (2018-2023)
  • Table 29. Sepsis Diagnostics Research Laboratories & Academic Institute , by Region USD Million (2018-2023)
  • Table 30. South America Sepsis Diagnostics, by Country USD Million (2018-2023)
  • Table 31. South America Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 32. South America Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 33. South America Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 34. South America Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 35. South America Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 36. South America Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 37. Brazil Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 38. Brazil Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 39. Brazil Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 40. Brazil Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 41. Brazil Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 42. Brazil Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 43. Argentina Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 44. Argentina Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 45. Argentina Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 46. Argentina Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 47. Argentina Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 48. Argentina Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 49. Rest of South America Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 50. Rest of South America Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 51. Rest of South America Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 52. Rest of South America Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 53. Rest of South America Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 54. Rest of South America Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 55. Asia Pacific Sepsis Diagnostics, by Country USD Million (2018-2023)
  • Table 56. Asia Pacific Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 57. Asia Pacific Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 58. Asia Pacific Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 59. Asia Pacific Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 60. Asia Pacific Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 61. Asia Pacific Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 62. China Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 63. China Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 64. China Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 65. China Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 66. China Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 67. China Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 68. Japan Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 69. Japan Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 70. Japan Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 71. Japan Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 72. Japan Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 73. Japan Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 74. India Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 75. India Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 76. India Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 77. India Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 78. India Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 79. India Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 80. South Korea Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 81. South Korea Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 82. South Korea Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 83. South Korea Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 84. South Korea Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 85. South Korea Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 86. Taiwan Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 87. Taiwan Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 88. Taiwan Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 89. Taiwan Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 90. Taiwan Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 91. Taiwan Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 92. Australia Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 93. Australia Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 94. Australia Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 95. Australia Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 96. Australia Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 97. Australia Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 99. Rest of Asia-Pacific Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 100. Rest of Asia-Pacific Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 101. Rest of Asia-Pacific Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 102. Rest of Asia-Pacific Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 103. Rest of Asia-Pacific Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 104. Europe Sepsis Diagnostics, by Country USD Million (2018-2023)
  • Table 105. Europe Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 106. Europe Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 107. Europe Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 108. Europe Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 109. Europe Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 110. Europe Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 111. Germany Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 112. Germany Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 113. Germany Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 114. Germany Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 115. Germany Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 116. Germany Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 117. France Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 118. France Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 119. France Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 120. France Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 121. France Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 122. France Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 123. Italy Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 124. Italy Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 125. Italy Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 126. Italy Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 127. Italy Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 128. Italy Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 129. United Kingdom Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 130. United Kingdom Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 131. United Kingdom Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 132. United Kingdom Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 133. United Kingdom Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 134. United Kingdom Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 135. Netherlands Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 136. Netherlands Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 137. Netherlands Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 138. Netherlands Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 139. Netherlands Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 140. Netherlands Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 141. Rest of Europe Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 142. Rest of Europe Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 143. Rest of Europe Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 144. Rest of Europe Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 145. Rest of Europe Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 146. Rest of Europe Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 147. MEA Sepsis Diagnostics, by Country USD Million (2018-2023)
  • Table 148. MEA Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 149. MEA Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 150. MEA Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 151. MEA Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 152. MEA Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 153. MEA Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 154. Middle East Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 155. Middle East Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 156. Middle East Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 157. Middle East Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 158. Middle East Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 159. Middle East Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 160. Africa Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 161. Africa Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 162. Africa Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 163. Africa Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 164. Africa Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 165. Africa Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 166. North America Sepsis Diagnostics, by Country USD Million (2018-2023)
  • Table 167. North America Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 168. North America Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 169. North America Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 170. North America Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 171. North America Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 172. North America Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 173. United States Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 174. United States Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 175. United States Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 176. United States Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 177. United States Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 178. United States Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 179. Canada Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 180. Canada Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 181. Canada Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 182. Canada Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 183. Canada Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 184. Canada Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 185. Mexico Sepsis Diagnostics, by Type USD Million (2018-2023)
  • Table 186. Mexico Sepsis Diagnostics, by Products USD Million (2018-2023)
  • Table 187. Mexico Sepsis Diagnostics, by Technology USD Million (2018-2023)
  • Table 188. Mexico Sepsis Diagnostics, by Teste types USD Million (2018-2023)
  • Table 189. Mexico Sepsis Diagnostics, by Method USD Million (2018-2023)
  • Table 190. Mexico Sepsis Diagnostics, by End User USD Million (2018-2023)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Sepsis Diagnostics: by Type(USD Million)
  • Table 203. Sepsis Diagnostics Microbiology , by Region USD Million (2025-2030)
  • Table 204. Sepsis Diagnostics Molecular Diagnostics , by Region USD Million (2025-2030)
  • Table 205. Sepsis Diagnostics Immunoassays , by Region USD Million (2025-2030)
  • Table 206. Sepsis Diagnostics Flow Cytometry , by Region USD Million (2025-2030)
  • Table 207. Sepsis Diagnostics Microfluidics , by Region USD Million (2025-2030)
  • Table 208. Sepsis Diagnostics Biomarkers , by Region USD Million (2025-2030)
  • Table 209. Sepsis Diagnostics: by Products(USD Million)
  • Table 210. Sepsis Diagnostics Blood Culture Media , by Region USD Million (2025-2030)
  • Table 211. Sepsis Diagnostics Assays & Reagents , by Region USD Million (2025-2030)
  • Table 212. Sepsis Diagnostics Instruments , by Region USD Million (2025-2030)
  • Table 213. Sepsis Diagnostics Software , by Region USD Million (2025-2030)
  • Table 214. Sepsis Diagnostics: by Technology(USD Million)
  • Table 215. Sepsis Diagnostics Blood Culture , by Region USD Million (2025-2030)
  • Table 216. Sepsis Diagnostics Immunoassays , by Region USD Million (2025-2030)
  • Table 217. Sepsis Diagnostics Molecular Diagnostics , by Region USD Million (2025-2030)
  • Table 218. Sepsis Diagnostics: by Teste types(USD Million)
  • Table 219. Sepsis Diagnostics Blood tests , by Region USD Million (2025-2030)
  • Table 220. Sepsis Diagnostics Confirmatory Tests , by Region USD Million (2025-2030)
  • Table 221. Sepsis Diagnostics Imaging tests , by Region USD Million (2025-2030)
  • Table 222. Sepsis Diagnostics Laboratory Tests , by Region USD Million (2025-2030)
  • Table 223. Sepsis Diagnostics Point-of-Care Tests , by Region USD Million (2025-2030)
  • Table 224. Sepsis Diagnostics: by Method(USD Million)
  • Table 225. Sepsis Diagnostics Automated Diagnostics , by Region USD Million (2025-2030)
  • Table 226. Sepsis Diagnostics Conventional Diagnostics , by Region USD Million (2025-2030)
  • Table 227. Sepsis Diagnostics: by End User(USD Million)
  • Table 228. Sepsis Diagnostics Hospitals , by Region USD Million (2025-2030)
  • Table 229. Sepsis Diagnostics Pathology & Reference Laboratories , by Region USD Million (2025-2030)
  • Table 230. Sepsis Diagnostics Research Laboratories & Academic Institute , by Region USD Million (2025-2030)
  • Table 231. South America Sepsis Diagnostics, by Country USD Million (2025-2030)
  • Table 232. South America Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 233. South America Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 234. South America Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 235. South America Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 236. South America Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 237. South America Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 238. Brazil Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 239. Brazil Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 240. Brazil Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 241. Brazil Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 242. Brazil Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 243. Brazil Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 244. Argentina Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 245. Argentina Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 246. Argentina Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 247. Argentina Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 248. Argentina Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 249. Argentina Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 250. Rest of South America Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 251. Rest of South America Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 252. Rest of South America Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 253. Rest of South America Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 254. Rest of South America Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 255. Rest of South America Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 256. Asia Pacific Sepsis Diagnostics, by Country USD Million (2025-2030)
  • Table 257. Asia Pacific Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 258. Asia Pacific Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 259. Asia Pacific Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 260. Asia Pacific Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 261. Asia Pacific Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 262. Asia Pacific Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 263. China Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 264. China Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 265. China Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 266. China Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 267. China Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 268. China Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 269. Japan Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 270. Japan Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 271. Japan Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 272. Japan Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 273. Japan Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 274. Japan Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 275. India Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 276. India Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 277. India Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 278. India Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 279. India Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 280. India Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 281. South Korea Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 282. South Korea Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 283. South Korea Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 284. South Korea Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 285. South Korea Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 286. South Korea Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 287. Taiwan Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 288. Taiwan Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 289. Taiwan Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 290. Taiwan Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 291. Taiwan Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 292. Taiwan Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 293. Australia Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 294. Australia Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 295. Australia Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 296. Australia Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 297. Australia Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 298. Australia Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 299. Rest of Asia-Pacific Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 300. Rest of Asia-Pacific Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 301. Rest of Asia-Pacific Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 302. Rest of Asia-Pacific Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 303. Rest of Asia-Pacific Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 304. Rest of Asia-Pacific Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 305. Europe Sepsis Diagnostics, by Country USD Million (2025-2030)
  • Table 306. Europe Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 307. Europe Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 308. Europe Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 309. Europe Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 310. Europe Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 311. Europe Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 312. Germany Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 313. Germany Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 314. Germany Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 315. Germany Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 316. Germany Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 317. Germany Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 318. France Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 319. France Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 320. France Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 321. France Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 322. France Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 323. France Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 324. Italy Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 325. Italy Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 326. Italy Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 327. Italy Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 328. Italy Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 329. Italy Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 330. United Kingdom Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 331. United Kingdom Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 332. United Kingdom Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 333. United Kingdom Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 334. United Kingdom Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 335. United Kingdom Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 336. Netherlands Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 337. Netherlands Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 338. Netherlands Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 339. Netherlands Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 340. Netherlands Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 341. Netherlands Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 342. Rest of Europe Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 343. Rest of Europe Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 344. Rest of Europe Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 345. Rest of Europe Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 346. Rest of Europe Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 347. Rest of Europe Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 348. MEA Sepsis Diagnostics, by Country USD Million (2025-2030)
  • Table 349. MEA Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 350. MEA Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 351. MEA Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 352. MEA Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 353. MEA Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 354. MEA Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 355. Middle East Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 356. Middle East Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 357. Middle East Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 358. Middle East Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 359. Middle East Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 360. Middle East Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 361. Africa Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 362. Africa Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 363. Africa Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 364. Africa Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 365. Africa Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 366. Africa Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 367. North America Sepsis Diagnostics, by Country USD Million (2025-2030)
  • Table 368. North America Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 369. North America Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 370. North America Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 371. North America Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 372. North America Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 373. North America Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 374. United States Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 375. United States Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 376. United States Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 377. United States Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 378. United States Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 379. United States Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 380. Canada Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 381. Canada Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 382. Canada Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 383. Canada Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 384. Canada Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 385. Canada Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 386. Mexico Sepsis Diagnostics, by Type USD Million (2025-2030)
  • Table 387. Mexico Sepsis Diagnostics, by Products USD Million (2025-2030)
  • Table 388. Mexico Sepsis Diagnostics, by Technology USD Million (2025-2030)
  • Table 389. Mexico Sepsis Diagnostics, by Teste types USD Million (2025-2030)
  • Table 390. Mexico Sepsis Diagnostics, by Method USD Million (2025-2030)
  • Table 391. Mexico Sepsis Diagnostics, by End User USD Million (2025-2030)
  • Table 392. Research Programs/Design for This Report
  • Table 393. Key Data Information from Secondary Sources
  • Table 394. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sepsis Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global Sepsis Diagnostics: by Products USD Million (2018-2023)
  • Figure 6. Global Sepsis Diagnostics: by Technology USD Million (2018-2023)
  • Figure 7. Global Sepsis Diagnostics: by Teste types USD Million (2018-2023)
  • Figure 8. Global Sepsis Diagnostics: by Method USD Million (2018-2023)
  • Figure 9. Global Sepsis Diagnostics: by End User USD Million (2018-2023)
  • Figure 10. South America Sepsis Diagnostics Share (%), by Country
  • Figure 11. Asia Pacific Sepsis Diagnostics Share (%), by Country
  • Figure 12. Europe Sepsis Diagnostics Share (%), by Country
  • Figure 13. MEA Sepsis Diagnostics Share (%), by Country
  • Figure 14. North America Sepsis Diagnostics Share (%), by Country
  • Figure 15. Global Sepsis Diagnostics share by Players 2023 (%)
  • Figure 16. Global Sepsis Diagnostics share by Players (Top 3) 2023(%)
  • Figure 17. Global Sepsis Diagnostics share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 20. BioMérieux (France) Revenue: by Geography 2023
  • Figure 21. Becton Dickinson Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Becton Dickinson Company (United States) Revenue: by Geography 2023
  • Figure 23. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 24. Danaher (United States) Revenue: by Geography 2023
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 27. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 29. T2 Biosystems (United States) Revenue, Net Income and Gross profit
  • Figure 30. T2 Biosystems (United States) Revenue: by Geography 2023
  • Figure 31. Luminex (United States) Revenue, Net Income and Gross profit
  • Figure 32. Luminex (United States) Revenue: by Geography 2023
  • Figure 33. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 34. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 35. Bruker (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bruker (United States) Revenue: by Geography 2023
  • Figure 37. EKF Diagnostics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. EKF Diagnostics (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Immunexpress (Australia) Revenue, Net Income and Gross profit
  • Figure 40. Immunexpress (Australia) Revenue: by Geography 2023
  • Figure 41. Global Sepsis Diagnostics: by Type USD Million (2025-2030)
  • Figure 42. Global Sepsis Diagnostics: by Products USD Million (2025-2030)
  • Figure 43. Global Sepsis Diagnostics: by Technology USD Million (2025-2030)
  • Figure 44. Global Sepsis Diagnostics: by Teste types USD Million (2025-2030)
  • Figure 45. Global Sepsis Diagnostics: by Method USD Million (2025-2030)
  • Figure 46. Global Sepsis Diagnostics: by End User USD Million (2025-2030)
  • Figure 47. South America Sepsis Diagnostics Share (%), by Country
  • Figure 48. Asia Pacific Sepsis Diagnostics Share (%), by Country
  • Figure 49. Europe Sepsis Diagnostics Share (%), by Country
  • Figure 50. MEA Sepsis Diagnostics Share (%), by Country
  • Figure 51. North America Sepsis Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • bioMérieux (France)
  • Becton Dickinson Company (United States)
  • Danaher (United States)
  • Abbott Laboratories (United States)
  • Roche Diagnostics (Switzerland)
  • T2 Biosystems (United States)
  • Luminex (United States)
  • Thermo Fisher Scientific (United States)
  • Bruker (United States)
  • EKF Diagnostics (United Kingdom)
  • Immunexpress (Australia)
Additional players considered in the study are as follows:
Response Biomedical (Canada) , Axis-Shield Diagnostics (United Kingdom) , CytoSorbents (United States).
Select User Access Type

Key Highlights of Report


Apr 2024 163 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sepsis Diagnostics Quantitative research analysis
Global Sepsis Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as bioMérieux (France), Becton Dickinson Company (United States), Danaher (United States), Abbott Laboratories (United States), Roche Diagnostics (Switzerland), T2 Biosystems (United States), Luminex (United States), Thermo Fisher Scientific (United States), Bruker (United States), EKF Diagnostics (United Kingdom) and Immunexpress (Australia) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing use of hospice for end-of-life care" is seen as one of major influencing trends for Sepsis Diagnostics Market during projected period 2023-2030.
The Sepsis Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Sepsis Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Small Molecule Targeted Cancer Therapy Comprehensive Study by Type (Monoclonal Antibodies, Small Molecules, Small Molecule Drug Conjugates), Application (Lymphoma, Melanoma, Multiple Myeloma, Breast ...
$ 3750
Artificial Vital Organs Comprehensive Study by Type (Artificial Liver, Artificial Heart, Artificial Pancreas, Artificial Kidney, Artificial Lungs), Application (Hospitals, Clinics, Research Centers, ...
$ 3500
Digital Genome Comprehensive Study by Application (Microbiology {Biological, Clinical, Industrial}, Reproductive & Genetic, Transplantation, Livestock and Agriculture, Forensics, Research and Develop...
$ 3750
Microalbumin Test Comprehensive Study by Type (Random Urine test, 24 hour urine test, Timed urine test), Application (Hospitals, Clinics, Diagnostics Laboratories, Others), End Users (Hospitals, Clin...
$ 3650
Artificial Blood Comprehensive Study by Type (Human Blood, Synthetic Blood, Animal Blood), Application (Cardiovascular diseases, Anemia, Organ transplant, Trauma, Others), End-use (Hospitals, Clinics...
$ 3350
Cryogenic Biobanking Services Comprehensive Study by Type (Ice Machines, Freezers, Alarms And Monitoring System, Refrigerators, Cryogenic Storage Systems, Accessories), Application (Biobaking, Regene...
$ 3750